Achiko Logo cropped.jpg
Achiko AG Production and Sales Update
21. Dezember 2022 07:42 ET | Achiko AG
AptameX™ Gen 2 Covid-19 rapid calibration outperforms Abbott Pan Bio and Clugene’s rapid tests in Indonesia in validation tests.Sample of 20 PCR Positive and 9 Negative samples, indicated a 100% match...
Achiko Logo cropped.jpg
2022 Ordinary Shareholders’ Meeting of Achiko AG: Shareholders Adopt All Proposals
20. Dezember 2022 15:03 ET | Achiko AG
ZURICH, Switzerland, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) held its Annual General Meeting today at 10:00 CET in Zurich....
Achiko Logo cropped.jpg
Achiko AG Announces Corporate Update Webcast
16. November 2022 10:38 ET | Achiko AG
ZURICH, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”), a healthcare technology company that is developing new...
Achiko Logo cropped.jpg
Achiko AG Production and Company Update
02. November 2022 07:34 ET | Achiko AG
Completing Production Pilot for Generation 2 of AptameX™ as a Precursor to Mass Commercial ProductionExpect to Commence Delivery to Sales and Marketing Contract with Nahdlatul Ulama on Commencement of...
Achiko Logo cropped.jpg
Achiko AG Appoints New Chief Financial Officer
07. Oktober 2022 07:30 ET | Achiko AG
ZURICH, Switzerland, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”), a healthcare...
Achiko Logo cropped.jpg
Achiko AG Reports First Half to June 30, 2022 Results and Provides Corporate Update as of September 30, 2022
03. Oktober 2022 07:33 ET | Achiko AG
Achiko reports an EBITDA loss of USD $1.9 million, compared to an EBITDA loss of USD $4.6 million for the six months ending June 30, 2021.Focal points of the first half year were completion of a major...
Achiko Logo cropped.jpg
Achiko AG – Investor Briefing
07. Juli 2022 15:22 ET | Achiko AG
ZURICH, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF, SIX: ACHI, ISIN CH0522213468) (“Achiko”, the “Company”), would like to invite investors and shareholders to a...
Achiko Logo cropped.jpg
Achiko AG Announces Annual Results for the Year Ended December 31, 2021
26. Juni 2022 19:30 ET | Achiko AG
ZURICH, Switzerland, June 26, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces its financial results for the year ended December...
Achiko Logo cropped.jpg
Achiko AG Publication of Annual Report and Annual Financial Statements 2021 to Occur by June 6, 2022
31. Mai 2022 07:30 ET | Achiko AG
ZURICH, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces that...
Achiko Logo cropped.jpg
Achiko AG Obtains CE Mark for AptameX™ Covid-19 Rapid Test
17. Mai 2022 07:30 ET | Achiko AG
Registered AptameX and Has Obtained a CE Mark, Allowing the Product to Be Sold in 27 Countries in the EUAptameX Has Unique Performance Advantages Over Other Rapid Tests Through its Use of DNA...